The Clinical BioManufacturing Facility is the University of Oxford’s GMP (Good Manufacturing Practice) manufacturing facility.
The Clinical BioManufacturing Facility has over 20 years experience producing biological Investigational Medicinal Products (IMPs) according to the principles of GMP for early phase clinical trials. We hold a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which allows us to manufacture a variety of products including viral vector and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products. All IMPs are manufactured and released in accordance with the European Clinical Trials Directive (2004). The facility can also import IMPs from outside the EU for use in clinical trials within the European Union.
We aim to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials.
Our GMP manufacturing facility enables us to meet the special demands for phase I/II clinical trials of novel biotech products within the academic and commercial sectors and to deliver effective short term treatments to the clinic providing long term benefits to the patient.
News
Professor Sir Andrew Pollard reveals unique insights into the world of science in a new podcast
28 April 2023
Oxford Vaccine Group and Pandemic Sciences Institute’s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.
Call for abstracts: International Pandemic Sciences Conference
13 April 2023
Abstract submission for the International Pandemic Sciences Conference 2023 - Making the Exceptional Routine has been extended to Friday 28 April 2023.
£12 million investment for Future Vaccines Manufacturing Hub
11 April 2023
A new Future Vaccines Manufacturing Hub – co-led by University of Oxford and University College London – aims to make the UK the global centre for discovering and manufacturing next-generation vaccines.